Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Scientists at the Stem Cell Research program at Boston Children's Hospital and Dana-Farber Cancer Institute/Harvard Medical School have devised a mouse model that lets researchers track every cell in the body, from the embryonic stage until adulthood.
There are immune cells in our bodies that directly destroy infected or cancer cells - they are called natural killer cells. Recently, a POSTECH research team has developed an integrative cancer therapy using adoptive natural killer cell therapy and chemotherapy.
The genetic information within our cells is what makes humans unique. The cell nucleus has a complex structure that harbors this genetic information.
Acute myeloid leukemia is an aggressive cancer of the blood-forming system. It affects the hematopoietic stem cells, or blood stem cells, of various white blood cells and of the red blood cells and platelets.
A new study released today in STEM CELLS suggests for the first time that regulatory T-cells (Treg) induced by mesenchymal stromal cells can yield an abundant replacement for naturally occurring T-cells, which are vital in protecting the body from infection.
Before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergo dramatic shifts.
A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse.
At the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, scientists have investigated how solute carriers (SLCs)—a large class of membrane transport proteins—affect the activity and potency of cytotoxic drugs, for example, those used to treat leukemia and other cancers.
In a genome-wide CRISPR-Cas9 screen published in Nature Immunology in January 2020, a group of researchers described a potential universal target on cancer cells.